HCPCS Level II code A9601 designates Flortaucipir F 18 injection, a diagnostic radiopharmaceutical used in PET imaging to visualize tau protein pathology. Nationally, this code is relevant for neuroimaging programs, neurologists, nuclear medicine physicians, and imaging facilities as the use of tau-targeted PET agents expands clinical and research applications in neurodegenerative disease evaluation. Payers frequently assess coverage policies for novel radiotracers based on clinical evidence, indication-specific utility, and cost considerations.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what A9601 represents, typical sites of service, and the clinical context for use in PET neuroimaging. The report highlights benchmark themes such as coverage variability, prior authorization trends, and coding nuances relevant to billing teams and revenue cycle staff. It also summarizes policy developments affecting radiopharmaceutical reimbursement and operational considerations for imaging centers. Data not available in the input will be noted where applicable.